Trial Profile
A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Anti HER2 small molecule imaging agent (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Diagnostic use
- Acronyms Affibody-3
- 24 Mar 2024 This trial has been Discontinued in Sweden (End date: 2024-02-05) according to European Clinical Trials Database record.
- 01 Sep 2023 Results investigating how [68Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC, published in the Journal of Nuclear Medicine
- 09 Dec 2021 According to an Affibody media release, data presented at the San Antonio Breast Cancer Symposium 2021.